Unveiling the mysteries of clopidogrel metabolism and efficacy

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 6, 2011, Pages 774-776

  Bonello, L ^a,b   Bonello, N ^c   Grosdidier, C ^b   Camoin Jau, L ^b,d  

^a HÔPITAL NORD   (France)

^b INSERM   (France)

^c TIMONE HOSPITAL   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19;

ALLELE; DRUG ABSORPTION; DRUG ACTIVATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; LOADING DRUG DOSE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HUMANS; MALE; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 81355142152     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.222     Document Type: Review

References (10)

1. CURE Investigators. Clopidogrel in Unstable angina to prevent Recurrent Events trial. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients erspectives undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
2. French Registry of ST-Elevation and Non-STElevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
3. Bonello, L. et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP. J. Am. Coll. Cardiol. 56, 919-933 (2010).
4. Hochholzer, W. et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55, 2427-2434 (2010).
5. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
6. Lewis, J.P. et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin. Pharmacol. Ther. 90, 568-574 (2011).
7. Simon, T. et al. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin. Pharmacol. Ther. 90, 561-567 (2011).
8. Bonello, L. et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J. Am. Coll. Cardiol. 56, 1630-1636 (2010).
9. Mega, J.L. et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376, 1312-1319 (2010).
10. Bonello, L. et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in coronary syndromes. J. Am. Coll. Cardiol. 58, 467-473 (2011).